Loading
A phase 2 trial of Gemcitabine and Gemcitabine + nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Salspera LLC, active and no longer recruiting.
Saltikva for Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT04589234 by Salspera LLC, with 60 participants enrolled, started 2020-10-20 and due to reach its primary completion in 2030-12-31. Interventions recorded: Salmonella-IL2, FOLFIRINOX Alone (Historical Controls) and Gemcitabine/Abraxane Alone (Historical Controls).
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.